Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry

被引：0

作者：

Sena Valcarcel

Javier Gallego

Paula Jimenez-Fonseca

Marc Diez

Eva Martínez de Castro

Raquel Hernandez

Virginia Arrazubi

Ana Custodio

Juana María Cano

Ana Fernández Montes

Ismael Macias

Laura Visa

Aitana Calvo

Rosario Vidal Tocino

Nieves Martínez Lago

María Luisa Limón

Mónica Granja

Mireia Gil

Paola Pimentel

Lola Macia-Rivas

Carolina Hernández Pérez

Montserrat Mangas

Alfonso Martín Carnicero

Paula Cerdà

Lucía Gomez Gonzalez

Francisco Garcia Navalon

Mª Dolores Mediano Rambla

Marta Martin Richard

Alberto Carmona-Bayonas

机构：

[1] Hospital Universitario Central de Asturias,Medical Oncology Department

[2] ISPA,Medical Oncology Department

[3] Hospital General Universitario de Elche,Medical Oncology Department

[4] Hospital Universitario Central de Asturias,Medical Oncology Department

[5] ISPA,Medical Oncology Department

[6] Hospital Universitario Vall d’Hebron,Medical Oncology Department

[7] Hospital Universitario Marqués de Valdecilla,Medical Oncology Department

[8] IDIVAL,Medical Oncology Department

[9] Hospital Universitario de Canarias,Medical Oncology Department

[10] Hospital Universitario de Navarra,Medical Oncology Department

[11] Instituto de Investigación Sanitaria de Navarra (IdiSNA),Medical Oncology Department

[12] Hospital Universitario La Paz,Medical Oncology Department

[13] CIBERONC CB16/12/00398,Medical Oncology Department

[14] Hospital General Universitario de Ciudad Real,Medical Oncology Department

[15] Complejo Hospitalario Universitario de Ourense,Medical Oncology Department

[16] Hospital Universitario Parc Tauli,Medical Oncology Department

[17] Hospital Universitario El Mar,Medical Oncology Department

[18] Hospital Universitario Gregorio Marañón,Medical Oncology Department

[19] Complejo Asistencial Universitario de Salamanca - IBSAL,Medical Oncology Department

[20] Complejo Hospitalario Universitario de A Coruña,Pharmacy Department

[21] Hospital Universitario Virgen del Rocío,Medical Oncology Department

[22] Hospital Universitario Clínico San Carlos Madrid,Medical Oncology Department

[23] Hospital General Universitario de Valencia,Medical Oncology Department

[24] Ciberonc CB16/12/0035,Medical Oncology Department

[25] Hospital Santa Lucía,Medical Oncology Department

[26] Hospital Universitario Central de Asturias,Medical Oncology Department

[27] Hospital Universitario Nuestra Señora de La Candelaria,Medical Oncology Department

[28] Hospital Galdakao-Usansolo,Hematology and Medical Oncology Department

[29] Medical Oncology Department,undefined

[30] Hospital San Pedro,undefined

[31] Hospital Santa Creu I Sant Pau,undefined

[32] Hospital General Universitario de Alicante,undefined

[33] Hospital Universitario Son Llatzer,undefined

[34] Hospital Universitario Virgen de La Macarena,undefined

[35] Catalan Institute of Oncology (ICO),undefined

[36] Hospital Universitario Morales Meseguer,undefined

[37] University of Murcia,undefined

[38] IMIB,undefined

[39] CP13/00126,undefined

[40] PI17/0050 (ISCIII& FEDER),undefined

来源：

Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷

关键词：

Gastroesophageal adenocarcinoma; HER2; Prognosis; Ramucirumab; Survival;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：4077 / 4089

页数：12

共 154 条

[1]

Alvarez-Manceñido F(2021)Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry Gastric Cancer 24 926-936

[2]

Jimenez-Fonseca P(2010)Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 687-697

[3]

Carmona-Bayonas A(2007)Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer J Clin Oncol 25 3853-3858

[4]

Bang Y-J(2016)On the effect of triplet or doublet chemotherapy in advanced gastric cancer: results from a national cancer registry J Natl Compr Canc Netw 14 1379-1388

[5]

van Cutsem E(2018)Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry Gastric Cancer 21 96-105

[6]

Feyereislova A(2018)Surgery for metastases for esophageal-gastric cancer in the real world: data from the AGAMENON national registry Eur J Surg Oncol 44 1191-1198

[7]

Bartsch R(2019)Multistate models: accurate and dynamic methods to improve predictions of thrombotic risk in patients with cancer Thromb Haemost 119 1849-1859

[8]

Wenzel C(2022)Causal considerations can inform the interpretation of surprising associations in medical registries Cancer Invest 40 1-13

[9]

Altorjai G(2018)A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: a nationwide health insurance database study PLoS ONE 13 e0205853-TPS369

[10]

Carmona-Bayonas A(2022)A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy versus chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015 J Clin Oncol 40 TPS369-1535

← 1 2 3 4 5 6 7 8 9 10 →